Literature DB >> 27738177

Biomarkers in NOA-04: another piece to the puzzle.

Andrew B Lassman1, Timothy F Cloughesy2.   

Abstract

Mesh:

Substances:

Year:  2016        PMID: 27738177      PMCID: PMC5063524          DOI: 10.1093/neuonc/now210

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  17 in total

1.  Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.

Authors:  Jan C Buckner; Edward G Shaw; Stephanie L Pugh; Arnab Chakravarti; Mark R Gilbert; Geoffrey R Barger; Stephen Coons; Peter Ricci; Dennis Bullard; Paul D Brown; Keith Stelzer; David Brachman; John H Suh; Christopher J Schultz; Jean-Paul Bahary; Barbara J Fisher; Harold Kim; Albert D Murtha; Erica H Bell; Minhee Won; Minesh P Mehta; Walter J Curran
Journal:  N Engl J Med       Date:  2016-04-07       Impact factor: 91.245

2.  Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.

Authors:  Linda Douw; Martin Klein; Selene Saa Fagel; Josje van den Heuvel; Martin Jb Taphoorn; Neil K Aaronson; Tjeerd J Postma; W Peter Vandertop; Jacob J Mooij; Rudolf H Boerman; Guus N Beute; Jasper D Sluimer; Ben J Slotman; Jaap C Reijneveld; Jan J Heimans
Journal:  Lancet Neurol       Date:  2009-08-07       Impact factor: 44.182

3.  A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.

Authors:  A B Karim; B Maat; R Hatlevoll; J Menten; E H Rutten; D G Thomas; F Mascarenhas; J C Horiot; L M Parvinen; M van Reijn; J J Jager; M G Fabrini; A M van Alphen; H P Hamers; L Gaspar; E Noordman; M Pierart; M van Glabbeke
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-10-01       Impact factor: 7.038

4.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

5.  Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.

Authors:  Benedikt Wiestler; David Capper; Martin Sill; David T W Jones; Volker Hovestadt; Dominik Sturm; Christian Koelsche; Anna Bertoni; Leonille Schweizer; Andrey Korshunov; Elisa K Weiß; Maximilian G Schliesser; Alexander Radbruch; Christel Herold-Mende; Patrick Roth; Andreas Unterberg; Christian Hartmann; Torsten Pietsch; Guido Reifenberger; Peter Lichter; Bernhard Radlwimmer; Michael Platten; Stefan M Pfister; Andreas von Deimling; Michael Weller; Wolfgang Wick
Journal:  Acta Neuropathol       Date:  2014-07-10       Impact factor: 17.088

6.  Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.

Authors:  Wolfgang Wick; Christoph Meisner; Bettina Hentschel; Michael Platten; Alissa Schilling; Benedikt Wiestler; Michael C Sabel; Susanne Koeppen; Ralf Ketter; Markus Weiler; Ghazaleh Tabatabai; Andreas von Deimling; Dorothee Gramatzki; Manfred Westphal; Gabriele Schackert; Markus Loeffler; Matthias Simon; Guido Reifenberger; Michael Weller
Journal:  Neurology       Date:  2013-09-25       Impact factor: 9.910

7.  Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.

Authors:  Wolfgang Wick; Patrick Roth; Christian Hartmann; Peter Hau; Makoto Nakamura; Florian Stockhammer; Michael C Sabel; Antje Wick; Susanne Koeppen; Ralf Ketter; Peter Vajkoczy; Ilker Eyupoglu; Rolf Kalff; Torsten Pietsch; Caroline Happold; Norbert Galldiks; Friederike Schmidt-Graf; Michael Bamberg; Guido Reifenberger; Michael Platten; Andreas von Deimling; Christoph Meisner; Benedikt Wiestler; Michael Weller
Journal:  Neuro Oncol       Date:  2016-07-01       Impact factor: 12.300

Review 8.  Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?

Authors:  Andrew B Lassman
Journal:  CNS Oncol       Date:  2015-11-06

9.  MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951.

Authors:  Martin J van den Bent; Lale Erdem-Eraslan; Ahmed Idbaih; Johan de Rooi; Paul H C Eilers; Wim G M Spliet; Wilfred F A den Dunnen; Cees Tijssen; Pieter Wesseling; Peter A E Sillevis Smitt; Johan M Kros; Thierry Gorlia; Pim J French
Journal:  Clin Cancer Res       Date:  2013-08-15       Impact factor: 12.531

10.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.

Authors:  Sevin Turcan; Daniel Rohle; Anuj Goenka; Logan A Walsh; Fang Fang; Emrullah Yilmaz; Carl Campos; Armida W M Fabius; Chao Lu; Patrick S Ward; Craig B Thompson; Andrew Kaufman; Olga Guryanova; Ross Levine; Adriana Heguy; Agnes Viale; Luc G T Morris; Jason T Huse; Ingo K Mellinghoff; Timothy A Chan
Journal:  Nature       Date:  2012-02-15       Impact factor: 69.504

View more
  2 in total

1.  Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.

Authors:  Andrew B Lassman; Khê Hoang-Xuan; Mei-Yin C Polley; Alba A Brandes; J Gregory Cairncross; Johan M Kros; Lynn S Ashby; Martin J B Taphoorn; Luis Souhami; Winand N M Dinjens; Nadia N Laack; Mathilde C M Kouwenhoven; Karen L Fink; Pim J French; David R Macdonald; Denis Lacombe; Minhee Won; Thierry Gorlia; Minesh P Mehta; Martin J van den Bent
Journal:  J Clin Oncol       Date:  2022-06-22       Impact factor: 50.717

2.  Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?

Authors:  Andrew B Lassman; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.